Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 8.01 (Other Events). BridgeBio submitted an FDA New Drug Application for encaleret targeting individuals with ADH1.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- BridgeBio submitted an FDA New Drug Application for encaleret targeting individuals with ADH1
- Regulatory filing advances encaleret toward potential approval and future commercialization
- Press release dated May 12, 2026 contains supporting details as Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.